Drug innovation and the product pipeline in the cardiometabolic space is lagging due to the inherent time and cost of evidence generation needed for regulatory evaluation and approvals.
There are several factors that can impact delivery success, drive up costs and potentially delay time to market. They include:
- Longer trial duration
- Intensive trial-related testing
- Poor medication adherence
- Delayed detection of key signals linked to endpoint capture
- Under-representation of the patient population for whom the treatment is intended
Medable’s offering in the cardiometabolic space offers a best-in-class series of digital products that are designed to provide an innovative, integrated digital solution around clinical workflows and established points of care between patients and their clinicians. They map and characterize a patient’s journey through healthcare and where and how they interact with the clinical study team.
The company’s products are intended to improve the patient experience, augment clinical care and drive more scientific rigor to data generation and timely endpoints specific to the target indication to accelerate research.
In a webinar scheduled for June 9 at 1pm ET, Medable will highlight how it is working to address drug development challenges and improve the patient experience in the context of clinical studies, with its best-in-class digital products geared for the cardiometabolic sector.
Among the webinar panelists are:
Claire Marsden, Ph.D, Vice President, DCT Solutions, Cardiovascular and Metabolic Disorders, Medable
Claire has worked in the biopharma and CRO industries for more than 25 years across all phases of clinical development including roles with big pharma companies, such as GSK, Pfizer, Novartis, and Bayer, as well as biotech businesses Alnylam and Lexicon. She has also worked for CROs such as IQVIA and its predecessor Quintiles, and Covance/LabCorp.
In her role within Medable, Claire collaborates with clients and internal teams to shape DCT solutions that are designed around the patient to optimize inclusivity and operational efficiency in order to transform drug development and registration.
MaryAnne Rizk, Ph.D, Chief Strategy Officer, Medable
Rizk joined Medable as the Chief Strategy Officer after leading the digital R&D cloud strategy at IQVIA for two years. Prior to that, Rizk was global vice president of CRO partnerships for Oracle for five years and previously was a director at Medidata Solutions and a project manager at Merck. In August, Rizk was named a PharmaVoice 100 leader. She
She is also a member of the Healthcare Businesswomen’s Association, Prix Galien Foundation Digital Advisory Board and Society for Clinical Research Sites (SCRS) Innovation Council.
Tammy D’Lugin-Monroe, Vice President, Global Head Therapeutic Strategy Innovation, Syneos Health
Prior to Syneos Health, D’Lugin-Monroe served in several different roles at CRO PPD and subsidiary business, Acurian, where she worked as an executive director and tailored strategic enrollment solutions and effective operational delivery across the PPD enterprise for clients. She also worked as a global senior project director in cardiovascular and metabolic diseases.
Photo: Warchi, Getty Images
